Cargando…

Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.

The level of galactosyltransferase activity was measured in the serum of 220 patients with a variety of solid tumours. There was a significantly greater proportion of patients with elevated galactosyltransferase in the group with metastatic disease (43%) than for the group with localised disease (16...

Descripción completa

Detalles Bibliográficos
Autores principales: Davey, R., Harvie, R., Cahill, J., Levi, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001336/
https://www.ncbi.nlm.nih.gov/pubmed/3006734
_version_ 1782135584389595136
author Davey, R.
Harvie, R.
Cahill, J.
Levi, J.
author_facet Davey, R.
Harvie, R.
Cahill, J.
Levi, J.
author_sort Davey, R.
collection PubMed
description The level of galactosyltransferase activity was measured in the serum of 220 patients with a variety of solid tumours. There was a significantly greater proportion of patients with elevated galactosyltransferase in the group with metastatic disease (43%) than for the group with localised disease (16%). Galactosyltransferase was elevated in 69% of patients with liver metastasis compared to 32% of patients with metastatic disease at sites other than liver and this difference was also significant. High resolution agarose isoelectric-focusing was used to determine the 'isoenzyme' pattern of serum galactosyltransferase of 6 patients with liver metastasis and 2 patients with primary hepatoma and these were compared to those of 6 patients with similar primary tumours without liver involvement. There were no qualitative differences in the patterns from the two groups. The average peak height for each of the 19 peaks of activity identified was generally higher in the group with liver involvement, except for those peaks known to contain little or no attached sialic acid. Liver involvement appears not to contribute in any specific way to the altered pattern of serum galactosyltransferase often seen in patients with solid tumours. The tumour rather than the liver is therefore the most likely source of these alterations.
format Text
id pubmed-2001336
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20013362009-09-10 Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement. Davey, R. Harvie, R. Cahill, J. Levi, J. Br J Cancer Research Article The level of galactosyltransferase activity was measured in the serum of 220 patients with a variety of solid tumours. There was a significantly greater proportion of patients with elevated galactosyltransferase in the group with metastatic disease (43%) than for the group with localised disease (16%). Galactosyltransferase was elevated in 69% of patients with liver metastasis compared to 32% of patients with metastatic disease at sites other than liver and this difference was also significant. High resolution agarose isoelectric-focusing was used to determine the 'isoenzyme' pattern of serum galactosyltransferase of 6 patients with liver metastasis and 2 patients with primary hepatoma and these were compared to those of 6 patients with similar primary tumours without liver involvement. There were no qualitative differences in the patterns from the two groups. The average peak height for each of the 19 peaks of activity identified was generally higher in the group with liver involvement, except for those peaks known to contain little or no attached sialic acid. Liver involvement appears not to contribute in any specific way to the altered pattern of serum galactosyltransferase often seen in patients with solid tumours. The tumour rather than the liver is therefore the most likely source of these alterations. Nature Publishing Group 1986-02 /pmc/articles/PMC2001336/ /pubmed/3006734 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Davey, R.
Harvie, R.
Cahill, J.
Levi, J.
Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.
title Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.
title_full Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.
title_fullStr Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.
title_full_unstemmed Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.
title_short Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.
title_sort serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001336/
https://www.ncbi.nlm.nih.gov/pubmed/3006734
work_keys_str_mv AT daveyr serumgalactosyltransferaseisoenzymepatternsofcancerpatientswithliverinvolvement
AT harvier serumgalactosyltransferaseisoenzymepatternsofcancerpatientswithliverinvolvement
AT cahillj serumgalactosyltransferaseisoenzymepatternsofcancerpatientswithliverinvolvement
AT levij serumgalactosyltransferaseisoenzymepatternsofcancerpatientswithliverinvolvement